Journal: Molecular Medicine Reports

Article Title: Naringin ameliorates intestinal injury in ulcerative colitis model mice by modulating the JAK2/STAT3 signaling pathway

doi: 10.3892/mmr.2026.13805

Figure Lengend Snippet: Naringin inhibits JAK2/STAT3 signaling and restores tight junction proteins in dextran sulfate sodium-induced colitis. (A) Representative western blotting images of p-JAK2, JAK2, p-STAT3, STAT3, IL-6, occludin, ZO-1 and β-actin expression in colon tissues. Densitometric semi-quantification of the relative protein expression levels of (B) p-JAK2/β-actin, (C) JAK2/β-actin, (D) p-JAK2/JAK2, (E) p-STAT3/β-actin, (F) STAT3/β-actin, (G) p-STAT3/STAT3, (H) IL-6/β-actin, (I) occludin/β-actin and (J) ZO-1/β-actin. Data are presented as mean ± SEM. n=3. *P<0.05 and **P<0.01 vs. control group; # P<0.05 and ## P<0.01 vs. normal group. One-way ANOVA followed by Tukey's post-hoc test was applied. N, normal group; C, control group; Nar, naringin group; Mes, mesalazine group; p-, phosphorylated; JAK2, Janus kinase 2; STAT3, signal transducer and activator of transcription 3; IL-6, ZO-1, zona occludens-1.

Article Snippet: Membranes were subsequently incubated separately with primary antibodies for p-JAK2 (1:1,000; cat. no. bs-2485R; BIOSS), JAK2 (1:1,000; cat. no. bs-0908R; BIOSS), p-STAT3 (1:1,000; cat. no. bs-1658R; BIOSS), STAT3 (1:1,000; cat. no. bs-55208R; BIOSS), occludin (1:1,000; cat. no. A2601; ABclonal Biotech Co., Ltd.), ZO-1 (1:1,000; cat. no. A0659; ABclonal Biotech Co., Ltd.) and β-actin (1:1,000; cat. no. ab8227; Abcam), and then with HRP-conjugated goat anti-rabbit IgG secondary antibody (1:5,000; cat. no. ab6721; Abcam).

Techniques: Western Blot, Expressing, Control

Journal: Molecular Medicine Reports

Article Title: Naringin ameliorates intestinal injury in ulcerative colitis model mice by modulating the JAK2/STAT3 signaling pathway

doi: 10.3892/mmr.2026.13805

Figure Lengend Snippet: Naringin suppresses JAK2/STAT3 activation in IL-6-stimulated Caco-2 cells with STAT3 silencing. (A) Western blot analysis of p-JAK2, JAK2, p-STAT3, STAT3, occludin and ZO-1 in Caco-2 cells under indicated treatments. (B) Validation of STAT3 knockdown efficiency: Relative STAT3 expression in cells transfected with siSTAT3 vs. siNC. ## P<0.01 vs. siNC. Densitometric semi-quantification of relative protein expression levels of (C) p-JAK2/β-actin, (D) JAK2/β-actin, (E) p-JAK2/JAK2, (F) p-STAT3/β-actin, (G) STAT3/β-actin, (H) p-STAT3/ STAT3, (I) occludin/β-actin, (J) ZO-1/β-actin. Data are presented as mean ± SEM. n=3. *P<0.05 and **P<0.01 vs. IL-6 group; ## P<0.01 vs. normal group; Δ P<0.05 and ΔΔ P<0.01 IL-6 + Nar group vs. IL-6 + Nar + siSTAT3 group. One-way ANOVA followed by Tukey's post-hoc test was applied. N, normal group; Nar, naringin group; Mes, mesalazine group; p-, phosphorylated; JAK2, Janus kinase 2; STAT3, signal transducer and activator of transcription 3; ZO-1, zona occludens-1; si, small interfering RNA; NC, negative control.

Article Snippet: Membranes were subsequently incubated separately with primary antibodies for p-JAK2 (1:1,000; cat. no. bs-2485R; BIOSS), JAK2 (1:1,000; cat. no. bs-0908R; BIOSS), p-STAT3 (1:1,000; cat. no. bs-1658R; BIOSS), STAT3 (1:1,000; cat. no. bs-55208R; BIOSS), occludin (1:1,000; cat. no. A2601; ABclonal Biotech Co., Ltd.), ZO-1 (1:1,000; cat. no. A0659; ABclonal Biotech Co., Ltd.) and β-actin (1:1,000; cat. no. ab8227; Abcam), and then with HRP-conjugated goat anti-rabbit IgG secondary antibody (1:5,000; cat. no. ab6721; Abcam).

Techniques: Activation Assay, Western Blot, Biomarker Discovery, Knockdown, Expressing, Transfection, Small Interfering RNA, Negative Control

Journal: The Journal of Cell Biology

Article Title: α-Syntrophin regulates ARMS localization at the neuromuscular junction and enhances EphA4 signaling in an ARMS-dependent manner

doi: 10.1083/jcb.200412008

Figure Lengend Snippet: ARMS and α-syntrophin enhanced the EphA4-induced Jak/Stat activation. (A) COS7 cells were transfected with EphA4, EphA4 KD mutant, or ARMS, and cell lysate was immunoblotted with antibodies against phosphorylated Tyr 1007/1008 of mouse Jak2, Tyr 1054/1055 of human Tyk2, Tyr 701 of Stat1, and Thr 202 /Tyr 204 of ERK1/2. p-Tyr; phosphorylated Tyr. (B) Quantification of the Western blots. y axis represents the fold change of tyrosine phosphorylation. n = 3; *, P < 0.05; **, P < 0.005. (C) COS7 cells were transfected with EphA4, ARMS, α-syntrophin, or α-syntrophin mPDZ, and cell lysate was immunoblotted with antibodies against phosphorylated Tyr 1007/1008 of mouse Jak2, Tyr 1054/1055 of human Tyk2, Tyr 701 of Stat1, and Thr 202 /Tyr 204 of ERK1/2. (D) Quantification of the Western blots. n = 3; *, P < 0.05; **, P < 0.005. Error bars represent the SEM.

Article Snippet: Polyclonal anti-HA antibodies, EphA4 antibody (sc-921), and Jak2 antibody (sc-278) were purchased from Santa Cruz Biotechnology, Inc., and the mAb that recognizes the α-isoform of Stat1 was obtained from Zymed Laboratories.

Techniques: Activation Assay, Transfection, Mutagenesis, Western Blot, Phospho-proteomics

Journal: iScience

Article Title: CCL7 promotes macrophage polarization and synovitis to exacerbate rheumatoid arthritis

doi: 10.1016/j.isci.2025.112177

Figure Lengend Snippet: CCL7 activates the CCR1/JAK2/STAT1 signaling pathway, influencing macrophage polarization (A–D) Immunohistochemical detection was used to evaluate the expression differences and quantitative statistics of pJAK2 and pSTAT1 proteins in synovial tissues from mice ( n = 10). Scale, 200 and 50 μm. (E and F) WB was utilized to detect the effects of fedratinib (24 h) on the pJAK2 and pSTAT1 proteins, along with a relative quantitative analysis ( n = 3). (G and H) In the presence of rmCCL7, 1 μM fedratinib (24 h), and their combination, WB was employed to monitor changes in the expression of iNOS and CD206 and to perform a relative quantitative analysis ( n = 3). (I) Effect of 1 μM fedratinib on CCL7 secretion from M1-polarized macrophages ( n = 3). (J and K) In macrophages, WB showed that LPS-induced CCL7 secretion was inhibited by 1 μM fedratinib and semi-quantitative statistical analysis ( n = 3). (L) RNA-seq was used to detect changes in the expression of downstream STAT1 gene ( n = 3). ns indicates not significant. Data are presented as the mean ± SD. Statistical analyses were performed using unpaired t tests (I and K) and one-way analysis of variance (ANOVA) followed by Tukey’s multiple comparison tests (B, D, F, and H). ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001, ∗∗∗∗ p < 0.0001.

Article Snippet: Phospho-JAK2 (Y1007 + Y1008) Recombinant Rabbit Monoclonal Antibody , HUABIO , Catalog# ET1607-34; RRID: AB_3069759.

Techniques: Immunohistochemical staining, Expressing, RNA Sequencing, Comparison

Journal: iScience

Article Title: CCL7 promotes macrophage polarization and synovitis to exacerbate rheumatoid arthritis

doi: 10.1016/j.isci.2025.112177

Figure Lengend Snippet:

Article Snippet: Phospho-JAK2 (Y1007 + Y1008) Recombinant Rabbit Monoclonal Antibody , HUABIO , Catalog# ET1607-34; RRID: AB_3069759.

Techniques: Recombinant, Adjuvant, Red Blood Cell Lysis, Lysis, Staining, CCK-8 Assay, Biomarker Discovery, Software

Journal: Neoplasia (New York, N.Y.)

Article Title: INCB16562, a JAK1/2 Selective Inhibitor, Is Efficacious against Multiple Myeloma Cells and Reverses the Protective Effects of Cytokine and Stromal Cell Support

doi:

Figure Lengend Snippet: Selective Inhibition of JAKs by INCB16562.

Article Snippet: The primary antibodies specific for the following proteins were used at the indicated dilutions: phospho-STAT3 (1:1000), STAT3 (1:1000), STAT5 (1:1000), phospho-JAK2 (1:1000), and JAK2 (1:1000; all from Cell Signaling, Beverly, MA); phospho-STAT5 (1:1000; Millipore, Temecula, CA); Mcl-1 (1:100), poly (ADP-ribose) polymerase (PARP; 1:100), Bcl-2 (1:100), Bcl-X L (1:100), α-actin (1:100; all from Santa Cruz Biotechnology, Santa Cruz, CA).

Techniques: Inhibition

Journal: Neoplasia (New York, N.Y.)

Article Title: INCB16562, a JAK1/2 Selective Inhibitor, Is Efficacious against Multiple Myeloma Cells and Reverses the Protective Effects of Cytokine and Stromal Cell Support

doi:

Figure Lengend Snippet: INCB16562 Is a Potent JAK1/2 Inhibitor.

Article Snippet: The primary antibodies specific for the following proteins were used at the indicated dilutions: phospho-STAT3 (1:1000), STAT3 (1:1000), STAT5 (1:1000), phospho-JAK2 (1:1000), and JAK2 (1:1000; all from Cell Signaling, Beverly, MA); phospho-STAT5 (1:1000; Millipore, Temecula, CA); Mcl-1 (1:100), poly (ADP-ribose) polymerase (PARP; 1:100), Bcl-2 (1:100), Bcl-X L (1:100), α-actin (1:100; all from Santa Cruz Biotechnology, Santa Cruz, CA).

Techniques: